Shenzhen Kexing Pharmaceutical Co., Ltd. – Trademark Portfolio
Entity Type: 99
Shenzhen Kexing Pharmaceutical Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include SANCTINUS.
B1601, Chuangyi Technology Building,
Keji Middle 1st Road, Maling Community, Yuehai Street, Nanshan District, Shenzhen, Guangdong
Showing of trademarks Trademarks
Trademark Classifications
Shenzhen Kexing Pharmaceutical Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Shenzhen Kexing Pharmaceutical Co., Ltd. have?
Shenzhen Kexing Pharmaceutical Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Shenzhen Kexing Pharmaceutical Co., Ltd. file in?
Shenzhen Kexing Pharmaceutical Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 10 (Medical Apparatus). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Shenzhen Kexing Pharmaceutical Co., Ltd.'s most well-known trademarks?
Shenzhen Kexing Pharmaceutical Co., Ltd.'s registered trademark portfolio includes well-known marks such as SANCTINUS. These are among 1 currently registered trademark in the portfolio.
What is Shenzhen Kexing Pharmaceutical Co., Ltd.'s trademark registration success rate?
Shenzhen Kexing Pharmaceutical Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.